These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 10699368)

  • 1. Human tumour and dendritic cell hybrids generated by electrofusion: potential for cancer vaccines.
    Scott-Taylor TH; Pettengell R; Clarke I; Stuhler G; La Barthe MC; Walden P; Dalgleish AG
    Biochim Biophys Acta; 2000 Mar; 1500(3):265-79. PubMed ID: 10699368
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Generation of dendritic cell-tumor cell hybrids by electrofusion for clinical vaccine application.
    Trevor KT; Cover C; Ruiz YW; Akporiaye ET; Hersh EM; Landais D; Taylor RR; King AD; Walters RE
    Cancer Immunol Immunother; 2004 Aug; 53(8):705-14. PubMed ID: 15048588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Generation of cell hybrids via a fusogenic cell line.
    Cheong SC; Blangenois I; Franssen JD; Servais C; Phan V; Trakatelli M; Bruyns C; Vile R; Velu T; Brandenburger A
    J Gene Med; 2006 Jul; 8(7):919-28. PubMed ID: 16602137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characteristics of hybrid cells obtained by dendritic cell/tumour cell fusion in a T-47D breast cancer cell line model indicate their potential as anti-tumour vaccines.
    Serhal K; Baillou C; Ghinea N; Fontanges P; Dupuy FP; Lemoine FM; Lacave R
    Int J Oncol; 2007 Dec; 31(6):1357-65. PubMed ID: 17982663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Electrofusion generates diverse DC-tumour cell hybrids for cancer immunotherapy.
    Weise JB; Hilpert F; Heiser A; Görögh T; Meyer JE; Weimer J; Krüger C; Rosenau A; Wieckhorst W; Arnold N; Pfisterer J; Kabelitz D; Maune S
    Anticancer Res; 2004; 24(2B):929-34. PubMed ID: 15161046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new genetic method to generate and isolate small, short-lived but highly potent dendritic cell-tumor cell hybrid vaccines.
    Phan V; Errington F; Cheong SC; Kottke T; Gough M; Altmann S; Brandenburger A; Emery S; Strome S; Bateman A; Bonnotte B; Melcher A; Vile R
    Nat Med; 2003 Sep; 9(9):1215-9. PubMed ID: 12925849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumour cell-dendritic cell fusion for cancer immunotherapy: comparison of therapeutic efficiency of polyethylen-glycol versus electro-fusion protocols.
    Lindner M; Schirrmacher V
    Eur J Clin Invest; 2002 Mar; 32(3):207-17. PubMed ID: 11895473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro evaluation of human hybrid cell lines generated by fusion of B-lymphoblastoid cells and ex vivo tumour cells as candidate vaccines for haematological malignancies.
    Mohamed YS; Dunnion D; Teobald I; Walewska R; Browning MJ
    Vaccine; 2012 Oct; 30(46):6578-87. PubMed ID: 22939910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Immunogenic reactivity of CTLs induced by electrofusion cells of human dendritic cells and gastric cancer cells].
    Imura K; Hayashi T; Yano Y; Naito K; Kouhara J; Ueda Y; Nakane K; Matsuura Y; Takeda A; Takeda T; Kawai K; Yamagishi H
    Gan To Kagaku Ryoho; 2004 Oct; 31(11):1797-9. PubMed ID: 15553719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allogeneic tumor-dendritic cell fusion vaccines for generation of broad prostate cancer T-cell responses.
    Lundqvist A; Palmborg A; Bidla G; Whelan M; Pandha H; Pisa P
    Med Oncol; 2004; 21(2):155-65. PubMed ID: 15299188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exposure to the electrofusion process can increase the immunogenicity of human cells.
    Hock BD; Roberts G; McKenzie JL; Gokhale P; Salm N; McLellan AD; Patton NW; Roake JA
    Cancer Immunol Immunother; 2005 Sep; 54(9):880-90. PubMed ID: 15926080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A dendritic cell based hybrid cell vaccine generated by electrofusion for immunotherapy strategies in HNSCC.
    Weise JB; Maune S; Görögh T; Kabelitz D; Arnold N; Pfisterer J; Hilpert F; Heiser A
    Auris Nasus Larynx; 2004 Jun; 31(2):149-53. PubMed ID: 15121224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapy of established tumour with a hybrid cellular vaccine generated by using granulocyte-macrophage colony-stimulating factor genetically modified dendritic cells.
    Cao X; Zhang W; Wang J; Zhang M; Huang X; Hamada H; Chen W
    Immunology; 1999 Aug; 97(4):616-25. PubMed ID: 10457215
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A biophysical approach to the optimisation of dendritic-tumour cell electrofusion.
    Sukhorukov VL; Reuss R; Endter JM; Fehrmann S; Katsen-Globa A; Gessner P; Steinbach A; Müller KJ; Karpas A; Zimmermann U; Zimmermann H
    Biochem Biophys Res Commun; 2006 Aug; 346(3):829-39. PubMed ID: 16780801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fusion of dendritic cells with multiple myeloma cells results in maturation and enhanced antigen presentation.
    Vasir B; Borges V; Wu Z; Grosman D; Rosenblatt J; Irie M; Anderson K; Kufe D; Avigan D
    Br J Haematol; 2005 Jun; 129(5):687-700. PubMed ID: 15916692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of cytotoxic T lymphocytes against human cancer cell lines using dendritic cell-tumor cell hybrids generated by a newly developed electrofusion technique.
    Imura K; Ueda Y; Hayashi T; Itoh T; Shimizu K; Tamai H; Yano Y; Naito K; Kohara J; Nakane K; Matsuura Y; Takeda A; Takeda T; Kawai K; Yamagishi H
    Int J Oncol; 2006 Sep; 29(3):531-9. PubMed ID: 16865268
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dendritic-tumor cell hybrids induce tumor-specific immune responses more effectively than the simple mixture of dendritic and tumor cells.
    Pinho MP; Sundarasetty BS; Bergami-Santos PC; Steponavicius-Cruz K; Ferreira AK; Stripecke R; Barbuto JA
    Cytotherapy; 2016 Apr; 18(4):570-80. PubMed ID: 26971685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced antitumor immunity derived from a novel vaccine of fusion hybrid between dendritic and engineered myeloma cells.
    Hao S; Bi X; Xu S; Wei Y; Wu X; Guo X; Carlsen S; Xiang J
    Exp Oncol; 2004 Dec; 26(4):300-6. PubMed ID: 15627063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cell fusion: an approach to generating constitutively proliferating human tumor antigen-presenting cells.
    Jantscheff P; Spagnoli G; Zajac P; Rochlitz CF
    Cancer Immunol Immunother; 2002 Sep; 51(7):367-75. PubMed ID: 12192536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dendritic cell-tumor cell hybrids enhance the induction of cytotoxic T lymphocytes against murine colon cancer: a comparative analysis of antigen loading methods for the vaccination of immunotherapeutic dendritic cells.
    Yasuda T; Kamigaki T; Nakamura T; Imanishi T; Hayashi S; Kawasaki K; Takase S; Ajiki T; Kuroda Y
    Oncol Rep; 2006 Dec; 16(6):1317-24. PubMed ID: 17089056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.